Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 331-338

  Yamaguchi, Hiroyuki ^a   Soda, Hiroshi ^b   Nakamura, Yoichi ^a   Takasu, Mineyo ^a   Tomonaga, Nanae ^a   Nakano, Hirofumi ^a   Doi, Seiji ^a   Nakatomi, Katsumi ^a   Nagashima, Seiji ^c   Takatani, Hiroshi ^c   Fukuda, Minoru ^d   Hayashi, Tomayoshi ^e   Tsukamoto, Kazuhiro ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b Sasebo Shiritsu Sogo Hospital   (Japan)

^c Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

^d Nagasaki Municipal Hospital   (Japan)

^e NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gefitinib; Non small cell lung cancer; SP A; SP D

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PHARMACOLOGICAL BIOMARKER; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXON; FEMALE; GENE DELETION; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; ADENOCARCINOMA; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETICS; LUNG TUMOR; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROTEIN KINASE INHIBITORS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 79953771942     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1325-x     Document Type: Article

References (33)

1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237-2246 (Pubitemid 46621858)
2. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158 (Pubitemid 37432975)
3. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109 (Pubitemid 41095044)
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500 (Pubitemid 38720929)
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)
6. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311 (Pubitemid 39209661)
7. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe y (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520 (Pubitemid 47050841)
8. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346 (Pubitemid 40425952)
9. Tanaka T, Nagai Y, Miyazawa H, Koyama N, Matsuoka S, Sutani A, Huqun, Udagawa K, Murayama Y, Nagata M, Shimizu Y, Ikebuchi K, Kanazawa M, Kobayashi K, Hagiwara K (2007) Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 98:246-252 (Pubitemid 44941878)
10. Hoshi K, Takakura H, Mitani Y, Tatsumi K, Momiyama N, Ichikawa Y, Togo S, Miyagi T, Kawai Y, Kogo Y, Kikuchi T, Kato C, Arakawa T, Uno S, Cizdziel PE, Lezhava A, Ogawa N, Hayashizaki Y, Shimada H (2007) Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res 13:4974-4983 (Pubitemid 47502061)
11. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, Tsukuda K, Ouchida M, Aoe M, Katayama H, Hiraki A, Sugi K, Kiura K, Date H, Shimizu N (2006) Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 12:43-48 (Pubitemid 43166174)
12. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T (2006) A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 8:335-341 (Pubitemid 44063810)
13. Persson A, Rust K, Chang D, Moxley M, Longmore W, Crouch e (1988) CP4: a pneumocyte-derived collagenous surfactant-associated protein. Evidence for heterogeneity of collagenous surfactant proteins. Biochemistry 27:8576-8584
14. Voorhout WF, Veenendaal T, Kuroki Y, Ogasawara Y, van Golde LM, Geuze HJ (1992) Immunocytochemical localization of surfactant protein D (SP-D) in type II cells, Clara cells, and alveolar macrophages of rat lung. J Histochem Cytochem 40:1589-1597
15. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T (2005) EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29:633-639 (Pubitemid 40577873)
16. Klein JM, McCarthy TA, Dagle JM, Snyder JM (2000) Antisense inhibition of epidermal growth factor receptor decreases expression of human surfactant protein A. Am J Respir Cell Mol Biol 22:676-684 (Pubitemid 30400246)
17. Klein JM, DeWild LJ, McCarthy TA (1998) Effect of tyrosine kinase inhibition on surfactant protein A gene expression during human lung development. Am J Physiol 274: L542-L551
18. Kuroki Y, Takahashi H, Chiba H, Akino T (1998) Surfactant proteins A and D: disease markers. Biochim Biophys Acta 1408:334-345 (Pubitemid 28517878)
19. Kishore U, Greenhough TJ, Waters P, Shrive AK, Ghai R, Kamran MF, Bernal AL, Reid KB, Madan T, Chakraborty T (2006) Surfactant proteins SP-A and SP-D: structure, function, and receptors. Mol Immunol 43:1293-1315 (Pubitemid 43356370)
20. Takahashi H, Kuroki Y, Honda Y, Shijubo N, Hirasawa M, Fujishima T, Akino T, Abe S (1996) Lipid analysis and surfactantassociated protein expression in lung adenocarcinoma cells from pleural effusion. Respiration 63:390-396 (Pubitemid 26356680)
21. Betz C, Papadopoulos T, Buchwald J, Dammrich J, Muller-Hermelink HK (1995) Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptasepolymerase chain reaction. Cancer Res 55:4283-4286
22. Mason RJ, Kalina M, Nielsen LD, Malkinson AM, Shannon JM (2000) Surfactant protein C expression in urethane-induced murine pulmonary tumors. Am J Pathol 156:175-182 (Pubitemid 30644450)
23. Zhang F, Pao W, Umphress SM, Jakowlew SB, Meyer AM, Dwyer-Nield LD, Nielsen LD, Takeda K, Gelfand EW, Fisher JH, Zhang L, Malkinson AM, Mason RJ (2003) Serum levels of surfactant protein D are increased in mice with lung tumors. Cancer Res 63:5889-5894 (Pubitemid 37187489)
24. Takahashi H, Fujishima T, Koba H, Murakami S, Kurokawa K, Shibuya Y, Shiratori M, Kuroki Y, Abe S (2000) Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 162:1109-1114
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
26. Shimizu T, Saijo N (2003) Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment. Nippon Rinsho 61:937-942
27. Soh J, Toyooka S, Aoe K, Asano H, Ichihara S, Katayama H, Hiraki A, Kiura K, Aoe M, Sano Y, Sugi K, Shimizu N, Date H (2006) Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 119:2353-2358 (Pubitemid 44546955)
28. Ohyanagi F, Nishio M, Horiike A, Taguchi F, Sato Y, Okumura S, Nakagawa K, Kasahara T, Horai T (2005) Serum levels of KL-6, SP-A, and SP-D in NSCLC patients treated with gefitinib. Jpn J Lung Cancer 45:823-828 (Pubitemid 43151703)
29. Mitsudomi T, Yatabe y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98:1817-1824 (Pubitemid 350002184)
30. Kitazaki T, Soda H, Doi S, Nakano H, Nakamura Y, Kohno S (2005) Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. Lung Cancer 50:19-24 (Pubitemid 41297465)
31. Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningen I (2002) Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 277:32258-32267 (Pubitemid 34969042)
32. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K (2006) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915-3921 (Pubitemid 44078075)
33. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366-377